Skip to main content
SpringerLink
Log in

Risiken und Prävention des Prostatakarzinoms

Ein Kommentar zur neuen S3-Leitlinie

Risks and prevention of prostate cancer

Commentary on the new S3 guideline

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Die Akzeptanz des Prostatakarzinoms als einer Volkskrankheit war Grundlage für die Entscheidung der Leitlinienkommission, den Themen Risiken und Prävention eigene Kapitel zu widmen. Die Analyse der umfangreichen Datenlage zu diesen Themen zeigt jedoch, dass etliche, scheinbar akzeptierte Risikofaktoren und Präventionsempfehlungen einer subtilen Überprüfung nicht Stand halten. Von daher wurden lediglich die Informationen von Männern über die Risikofaktoren Alter und genetische Belastung als Empfehlung aufgenommen. Während die Rolle der Ernährung insgesamt bei der Entstehung eines Prostatakarzinoms unbestritten bleibt, ist die Datenlage für einzelne Nahrungsstoffe sehr widersprüchlich. Positive interventionelle Studienergebnisse liegen nicht vor. Von daher wurden seitens der Kommission allgemeine Empfehlungen zu Ernährung und Lifestyle abgegeben, die auch andere Malignome und das Risiko für Herz-Kreislauf-Erkrankungen einschließen. Neue Ergebnisse prospektiver Studien zur Chemoprävention wurden in ein Statement eingearbeitet. Wegen der bislang fehlenden Zulassung von 5α-Reduktasehemmern zur Prävention des Prostatakarzinoms wurde von einer Empfehlung abgesehen.

Abstract

Acceptance of prostate cancer as an endemic disease was the basis for the decision reached by the guideline committee to devote a chapter to the topic of risks and prevention of prostate cancer. Analysis of the substantial data regarding these subjects, however, shows that a number of apparently accepted risk factors and recommendations for prevention do not withstand subtle assessment. For this reason, only information concerning the risk factors of age and genetic predisposition is obtained from men. While the role of nutrition in the pathogenesis of prostate cancer remains beyond dispute, data on individual food items are very contradictory. Positive results of interventional studies are not available. Thus, the committee issued general recommendations on nutrition and lifestyle which also include other malignant tumors and the risk for cardiovascular disease. New findings of prospective studies on chemoprevention were incorporated into a statement. Since 5-alpha-reductase inhibitors have not yet been approved for prevention of prostate cancer, no recommendation was given.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Albrecht M, Jiang W, Kumi-Diaka J et al (2004) Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 7:274–283

    Article  CAS  PubMed  Google Scholar 

  2. Andriole GL (2009) Headline Results of the REDUCE Trial: The effect of dutasteride on prostate cancer risk reduction. 107 th Annual Meeting, American Urological Association, Chicago

  3. Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47:1071–1078

    Article  CAS  PubMed  Google Scholar 

  4. Cross AJ, Peters U, Kirsh VA et al (2005) A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res 65:11779–11784

    Article  CAS  PubMed  Google Scholar 

  5. Dennis LK, Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13:72–79

    Article  PubMed  Google Scholar 

  6. Dennis LK, Dawson DV, Resnick MI (2002) Vasectomy and the risk of prostate cancer: a meta-analysis examining vasectomy status, age at vasectomy, and time since vasectomy. Prostate Cancer Prostatic Dis 5:193–203

    Article  CAS  PubMed  Google Scholar 

  7. Dennis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60:78–83

    Article  PubMed  Google Scholar 

  8. Deutsche Gesellschaft für Urologie (2009) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. DGU, Berlin

  9. Etminan M, Takkouche B, Caamano-Isorna F (2004) The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 13:340–345

    CAS  PubMed  Google Scholar 

  10. Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt und der Freistaaten Sachsen und Thüringen. Krebsinzidenz 2001 und 2002 im Erfassungsgebiet des Gemeinsamen Krebsregisters. Jahresbericht. 2005 (cited: 2009 Juni 22), http://www.berlin.de/imperia/md/content/gkr/publikationen/jahresberichte/jb2001_02.pdf

  11. Giovannucci E, Rimm EB, Stampfer MJ et al (1997) Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 6:557–563

    CAS  PubMed  Google Scholar 

  12. Graham S, Haughey B, Marshall J et al (1983) Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst 70:687–692

    CAS  PubMed  Google Scholar 

  13. Hebert JR, Hurley TG, Olendzki BC et al (1998) Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 90:1637–1647

    Article  CAS  PubMed  Google Scholar 

  14. Johns LE, Houlston RS (2003) A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 91:789–794

    Article  CAS  PubMed  Google Scholar 

  15. Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15:2056–2062

    Article  PubMed  Google Scholar 

  16. Kramer BS, Hagerty KL, Justman S et al (2009) Use of 5-alphareductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 27:1502–1516

    Article  CAS  PubMed  Google Scholar 

  17. Kurahashi N, Iwasaki M, Sasazuki S et al (2007) Japan Public Health Center-Based Prospective Study Group. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 16:538–545

    Article  CAS  PubMed  Google Scholar 

  18. Kushi LH, Byers T, Doyle C et al (2006) American cancer society 2006 Nutrition and physical activity guidelines advisory committee. American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 56:254–281

    Article  PubMed  Google Scholar 

  19. Lippman SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E cancer prevention trial (SELECT). JAMA 301:39–51

    Article  CAS  PubMed  Google Scholar 

  20. Lucia MS, Epstein JI, Goodman PJ et al (2007) Finasteride and high-grade prostate cancer in the prostate cancer prevention trial. J Natl Cancer Inst 99:1375–1383

    Article  CAS  PubMed  Google Scholar 

  21. MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17(8):989–1003

    Article  PubMed  Google Scholar 

  22. Morton RA Jr (1994) Racial differences in adenocarcinoma of the prostate in North American men. Urology 44:637–645

    Article  PubMed  Google Scholar 

  23. Nelson WG (2007) Prostate cancer prevention. Curr Opin Urol 17:157–167

    Article  PubMed  Google Scholar 

  24. Ozasa K, Nakao M, Watanabe Y et al (2004) Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 95:65–71

    Article  CAS  PubMed  Google Scholar 

  25. Ries LAG, Melbert D, Krapcho M et al (2007) SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Section 23: Prostate. (cited: 2009 Juli 01), http://www.seer.cancer.gov/csr/1975_2004/results_merged/sect_23_prostate.pdf

  26. Schröder FH, Hugosson J, Roobol MJ et al (2009) ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328

    Article  PubMed  Google Scholar 

  27. Strickler HD, Wylie-Rosett J, Rohan T et al (2001) The relation of type 2 diabetes and cancer. Diabetes Technol Ther 3:263–274

    Article  CAS  PubMed  Google Scholar 

  28. Taylor ML, Mainous AG 3rd, Wells BJ (2005) Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 37:506–512

    PubMed  Google Scholar 

  29. Teillac P, Abrahamsson PA (2006) The prostate cancer prevention trial and its implications for clinical practice: a European consensus. Eur Urol 5(Suppl):640–646

    Article  Google Scholar 

  30. Thompson IM, Goodman PJ, Tangen CM (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224

    Article  CAS  PubMed  Google Scholar 

  31. Thompson IM, Lucia MS, Redman MW et al (2007) Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 178:107–110

    Article  PubMed  Google Scholar 

  32. Wertz K, Siler U, Goralczyk R (2004) Lycopene: modes of action to promote prostate health. Arch Biochem Biophys 430:127–134

    Article  CAS  PubMed  Google Scholar 

  33. Wilt TJ, MacDonald R, Hagerty K et al (2008) Five-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev CD007091

  34. Zeegers MP, Jellema A, Ostrer H (2003) Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 97:1894–1903

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Urologie, EuromedClinic, Europa-Allee 1, 90763, Fürth, Deutschland

    B.J. Schmitz-Dräger & E. Bismarck

  2. Urologische Klinik, St. Josef-Hospital, Troisdorf, Deutschland

    G. Lümmen

Authors
  1. B.J. Schmitz-Dräger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Bismarck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Lümmen
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Mitglieder des Arbeitskreises Prävention, Umwelt und Komplementärmedizin (PUK)

Corresponding author

Correspondence to B.J. Schmitz-Dräger.

Additional information

Die Mitglieder des Arbeitskreises PUK sind: J. Altwein, München, C. Fischer, Bayreuth, T. Klotz, Amberg, G. Lümmen, Troisdorf, V. Rohde, Bad Schwartau, R. Schäfer, Bonn, B. Schmitz-Dräger, Fürth, F. Sommer, Hamburg, A. Schroeder, Neumünster, P. Thelen, Göttingen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmitz-Dräger, B., Bismarck, E., Lümmen, G. et al. Risiken und Prävention des Prostatakarzinoms. Urologe 49, 233–237 (2010). https://doi.org/10.1007/s00120-010-2240-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-010-2240-9

Schlüsselbegriffe

Keywords

Search

Navigation